Cargando…

Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials

BACKGROUND: Identifying the best markers to judge the adequacy of lipid‐lowering treatment is increasingly important for coronary heart disease (CHD) prevention given that several novel, potent lipid‐lowering therapies are in development. Reductions in LDL‐C, non‐HDL‐C, or apoB can all be used but w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thanassoulis, George, Williams, Ken, Ye, Keying, Brook, Robert, Couture, Patrick, Lawler, Patrick R., de Graaf, Jacqueline, Furberg, Curt D., Sniderman, Allan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187506/ https://www.ncbi.nlm.nih.gov/pubmed/24732920 http://dx.doi.org/10.1161/JAHA.113.000759

Ejemplares similares

Regulation of plasma LDL: the apoB paradigm
por: Sniderman, Allan D., et al.
Publicado: (2009)

The causal exposure model of vascular disease
por: Sniderman, Allan D., et al.
Publicado: (2011)

A Comparison of Lipids and apoB in Asian Indians and Americans
por: Singh, Kavita, et al.
Publicado: (2021)

ApoB and Non‐HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk
por: Johannesen, Camilla D. L., et al.
Publicado: (2022)

The LDL-C/ApoB ratio predicts cardiovascular and all-cause mortality in the general population
por: Xiao, Li, et al.
Publicado: (2023)

Utility of non-HDL-C and apoB targets in the context of new more aggressive lipid guidelines
por: Quispe, Renato, et al.
Publicado: (2021)

Do statins lower testosterone and does it matter?
por: Sniderman, Allan D, et al.
Publicado: (2013)

Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated
por: Sniderman, Allan D., et al.
Publicado: (2018)

Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements
por: Lai, Jiacheng, et al.
Publicado: (2021)

Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk
por: Glavinovic, Tamara, et al.
Publicado: (2022)

The value of the apoB/apoAΙ ratio and the non-HDL-C/HDL-C ratio in predicting carotid atherosclerosis among Chinese individuals with metabolic syndrome: a cross-sectional study
por: Qin, Guangming, et al.
Publicado: (2015)

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
por: Contois, John H., et al.
Publicado: (2023)

Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study
por: Yao, Tianci, et al.
Publicado: (2022)

Discordantly normal ApoB relative to elevated LDL-C in persons with metabolic disorders: A marker of atherogenic heterogeneity
por: Razavi, Alexander C., et al.
Publicado: (2021)

LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker
por: Aggarwal, Dr Jyoti, et al.
Publicado: (2021)

Leptin and adiponectin in relation to body fat percentage, waist to hip ratio and the apoB/apoA1 ratio in Asian Indian and Caucasian men and women
por: Smith, Jessica, et al.
Publicado: (2006)

Ratio of apoB/LDL: a potential clinical index for vascular cognitive impairment
por: Qian, Cheng, et al.
Publicado: (2016)

Nutrient patterns are associated with discordant apoB and LDL: a population-based analysis
por: Mazidi, Mohsen, et al.
Publicado: (2022)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone
por: Enomoto, Mika, et al.
Publicado: (2011)

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics
por: Björnson, E., et al.
Publicado: (2019)

ApoD Mediates Binding of HDL to LDL and to Growing T24 Carcinoma
por: Braesch-Andersen, Sten, et al.
Publicado: (2014)

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
por: Sniderman, Allan D., et al.
Publicado: (2016)

A Novel Variant in APOB Gene Causes Extremely Low LDL-C Without Known Adverse Effects
por: Surakka, Ida, et al.
Publicado: (2020)

Trends in LDL-C and Non-HDL-C Levels with Age
por: Zhang, Peng, et al.
Publicado: (2020)

Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake
por: Tognon, Gianluca, et al.
Publicado: (2012)

Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II
por: Shahid, Saleem Ullah, et al.
Publicado: (2016)

Analysis of apoB Concentrations Across Early Adulthood and Predictors for Rates of Change Using CARDIA Study Data
por: Wilkins, John T., et al.
Publicado: (2022)

Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2017)

Oxidative modifications of foetal LDL-c and HDL-c lipoproteins in preeclampsia
por: León-Reyes, G., et al.
Publicado: (2018)

The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptions
por: Furberg, Curt D
Publicado: (2001)

Role of Lipid Profile and Its Relative Ratios (Cholesterol/HDL-C, Triglyceride/HDL-C, LDL-C/HDL-C, WBC/HDL-C, and FBG/HDL-C) on Admission Predicts In-Hospital Mortality COVID-19
por: Mohammadshahi, Jafar, et al.
Publicado: (2023)

Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate
por: Dandan, Mohamad, et al.
Publicado: (2023)

ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels
por: Jun, Ji Eun, et al.
Publicado: (2018)

ApoB100-LDL Acts as a Metabolic Signal from Liver to Peripheral Fat Causing Inhibition of Lipolysis in Adipocytes
por: Skogsberg, Josefin, et al.
Publicado: (2008)

The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it
por: Xiong, Xiaowei, et al.
Publicado: (2015)

Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State
por: Miida, Takashi, et al.
Publicado: (2017)

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report
por: Reeskamp, Laurens F., et al.
Publicado: (2021)

Higher prevalence of elevated LDL-C than non-HDL-C and low statin treatment rate in elderly community-dwelling Chinese with high cardiovascular risk
por: Kuang, YaShu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6kasgfkm81tcsp4g3d9dt0jdbj